Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis.
Jin-Kai WangYang LiXiao-Lu ZhaoYuan-Bin LiuJing TanYu-Ying XingDilare AdiYong-Tao WangZhen-Yan FuYi-Tong MaSong-Mei LiuYong LiuYan WangXiong-Jie ShiXiao-Yi LuBao- Liang SongJie LuoPublished in: Circulation (2022)
PK regulates circulating cholesterol levels through binding to LDLR and inducing its lysosomal degradation. Ablation of PK stabilizes LDLR, decreases LDL cholesterol, and prevents atherosclerotic plaque development. This study suggests that PK is a promising therapeutic target to treat atherosclerotic cardiovascular disease.